长春瑞滨联合希罗达对蒽环类/紫杉类治疗后复发转移性乳腺癌的疗效观察

目的探讨长春瑞滨联合希罗达方案对蒽环类/紫杉类治疗后晚期复发转移乳腺癌的近期疗效和不良反应。方法40例应用蒽环类/紫杉类治疗后复发转移性乳腺癌患者，长春瑞滨25 mg/m²，静脉快速滴入，第1、8天；希罗达1 000 mg/m²,早晚两次餐后30 min口服，连用14天，21天为1周期，每例患者至少接受2周期的治疗。结果40例患者完全缓解（CR）3例，部分缓解（PR）16例，病情稳定(SD)14例，病情进展（PD）7例,总有效率47.5%，临床获益率为70%，中位疾病进展时间(TTP)为8.5月。常见不良反应为骨髓抑制、消化道反应、手足综合征、神经毒性，少数患者出现口腔炎、头晕、乏力和胸闷等。结论长春瑞滨联合希罗达方案对紫杉/蒽环类治疗后复发转移乳腺癌疗效确切。治疗过程中患者耐受性好，不良反应轻。

Effects of Vinorelbine Combined with Xeloda in Anthracycline-and Taxane-pretreated Patients with Relapsed Metastatic Breast Cancer

ObjectiveTo evaluate the short-term efficacy and adverse reactions of vinorelbine combined with xeloda to patients with recurrent and metastatic breast cancer after taxane and anthracycline treatment.MethodsForty patients with recurrent metastatic breast cancer after taxane and anthracycline treatment were recruited. Vinorelbine 25 mg/m² on day 1 and day 8, capecitabine 1 000 mg/m²,twice daily on day 1 to 14.Three weeks was one cycle.At least two cycles were given to each patient.ResultsOf the 40 patients,3 achieved CR,17 achieved PR,16 achieved SD,4 achieved PD,with a total response rate of 47.5%, with a clinical benefit response 70%.The median time to disease progression was 8.5 months.The common adverse reactions were myelosuppression，gastrointestinal reactions,hand-foot syndrome and neurotoxicity.Conclusionvinorelbine combined with capecitabine is an effective rigmens in the treatment of patients with relapsed and metastatic breast cancer,especially for those who have failed in chemotherapy with taxane and anthracycline.The therapy is well tolerated but has mild adverse reactions．